Consensus Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-17 am EDT			5-day change	1st Jan Change
17.98 ^HKD	-1.21%		+6.01%	+29.35%

May. 14	Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China	MT
May. 14	Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration	CI

Evolution of the average Target Price on Shanghai Henlius Biotech, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a088bf8b98c4c0dc0e29.E9i4JiLU8aA_Twtq_IY9vPNse9_bXC43Owy3MYgwD2M.aa_wE2Wgvs5OOmUMzslw2KMiLbu4NHZxY2TfHL9caBBhkupzaO2u4mk-fA~adf02ca8839249cfd404954f2351a4f1

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.64 CNY

Average target price

16.7 CNY

Spread / Average Target

+0.35%

High Price Target

23.05 CNY

Spread / Highest target

+38.48%

Low Price Target

8.352 CNY

Spread / Lowest Target

-49.82%

Consensus detail

Consensus revision (last 18 months)

Ratings for Shanghai Henlius Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar